Which Model of Stroke Unit Is Better for Stroke Patient Management?

The increasing prevalence of cerebrovascular diseases has made urgent the need to develop timely and effective treatment strategies to tackle this health problem. Stroke units (SUs) appear to be the ideal setting where the management of acute stroke patients, including specific treatments as thrombolysis, may be optimized. Which model of SU gives the best results is still an unsettled issue. The more intensive and timely multidisciplinary approach to the acute phase of stroke, the management of medical complications, and the earlier and more focused rehabilitation, are likely the most qualifying aspects of our Neurovascular treatment unit.

[1]  M. Kaste,et al.  Economic burden of stroke and the evaluation of new therapies. , 1998, Public health.

[2]  M. Hill,et al.  Stroke units in Canada. , 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[3]  T. Olsen,et al.  Treatment and rehabilitation on a stroke unit improves 5-year survival. A community-based study. , 1999, Stroke.

[4]  G. Albers,et al.  Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. , 1999, JAMA.

[5]  H. Diener,et al.  European Stroke Initiative Recommendations for Stroke Management – Update 2003 , 2003, Cerebrovascular Diseases.

[6]  G. Hankey,et al.  Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations* , 1999, The Lancet.

[7]  S. Sidney,et al.  Short-term prognosis after emergency department diagnosis of TIA. , 2000, JAMA.

[8]  K. Asplund,et al.  A non-intensive stroke unit reduces functional disability and the need for long-term hospitalization. , 1985, Stroke.

[9]  Silvana Quaglini,et al.  Role of Monitoring in Management of Acute Ischemic Stroke Patients , 2003, Stroke.

[10]  M. Brainin,et al.  Acute stroke treatment in Europe: a questionnaire‐based survey on behalf of the EFNS Task Force on acute neurological stroke care , 2003, European journal of neurology.

[11]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[12]  M. Kaste,et al.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) , 1998, The Lancet.

[13]  N. Maurits,et al.  Admitting Acute Ischemic Stroke Patients to a Stroke Care Monitoring Unit Versus a Conventional Stroke Unit: A Randomized Pilot Study , 2003, Stroke.

[14]  P. Langhorne,et al.  Association between physiological homeostasis and early recovery after stroke. , 2000, Stroke.

[15]  K. Asplund,et al.  Costs and Gains in Stroke Prevention: European Perspective , 1993 .

[16]  Langhorne,et al.  Collaborative systematic review of the randomised trials of organised inpatient (stroke unit) care after stroke , 1997, BMJ.

[17]  S. Slørdahl,et al.  Stroke unit treatment. 10-year follow-up. , 1999, Stroke.

[18]  M. Brainin,et al.  Acute neurological stroke care in Europe: results of the European Stroke Care Inventory , 2000, European journal of neurology.

[19]  S. Slørdahl,et al.  Stroke unit treatment. Long-term effects. , 1997, Stroke.

[20]  M. Kaste,et al.  Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) , 1995, JAMA.

[21]  P. Langhorne,et al.  Do stroke units save lives? , 1993, The Lancet.